VACUNAS CANDIDATAS
COVID-19

 

Listado actualizado de los 287 desarrollos con relación a la vacuna contra el covid-19 en todo el mundo.

Tipo de Vacuna CandidataPlataformaDesarrolladorEstado de la evaluación clínica

3 nanopartículas lipídicas de ARNm

ARN

BioNTech/Fosun Pharma/Pfizer

socio CAEME

Aprobada

Inactivada

Inactivada

Wuhan Institute of Biological Products/Sinopharm

Aprobada

ChAdOx1-S

Vector viral no replicante

University of Oxford/AstraZeneca

socio CAEME

Aprobada

Gam-COVID-Vac Adeno-based

Vector viral no replicante

Gamaleya Research Institute

Aprobada

Ad26 – Adenovirus recombinante serotipo 26

Vector viral no replicante

Janssen Pharmaceutical Companies

socio CAEME

Aprobada

ARNm encapsulado en nanopartículas lipídicas (LNP)

ARN

Moderna/NIAID

Aprobada

Inactivada + alumbre

Inactivada

Sinovac

Aprobada

Inactivada

Inactivada

Beijing Institute of Biological Products/Sinopharm

Aprobada

Vector de adenovirus tipo 5

Vector viral no replicante

CanSino Biological Inc./Beijing Institute of Biotechnology

Aprobada

Whole-Virion Inactivated

Inactivada

Bharat Biotech

Fase 3

Vacuna de nanopartículas de glucoproteína del CoV-2 SARS, recombinante, de longitud completa, adyuvada con Matrix M

Subunidad Proteica

Novavax

Fase 3

SARS-CoV-2 mRNA vaccine (ARCoV)

ARN

Walvax Biotechnology and Suzhou Abogen Biosciences

Fase 3

Proteína recombinante, adyuvada (Dímero RBD)

Subunidad Proteica

Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology Chinese Academy of Sciences

Fase 3

VLA2001

Inactivada

Valneva / National Institute for Health Research / United Kingdom

Fase 3

ARNm

ARN

Curevac

Fase 3

Inactivated SARS-CoV-2 vaccine (Vero cell)

Inactivada

Shenzhen Kangtai Biological Products Co Ltd.

Fase 3

EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)

Subunidad Proteica

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Fase 3

Inactivada

Inactivada

Chinese Academy of Medical Sciences

Fase 3

CIGB-66 (RBD+aluminium hydroxide)  

Subunidad Proteica

Center for Genetic Engineering and Biotechnology (CIGB)

Fase 3

Inactivada

Inactivada

Research Institute for Biological Safety Problems/Rep of Kazakhstan

Fase 3

Vacuna de ADN plasmídico

ADN

Osaka University/ AnGes/ Takara Bio

Fase 3

Vacuna de ADN plasmídico

ADN

Zydus Cadila

Fase 3

Vacuna de ADN plasmídico con electroporación

ADN

Inovio Pharmaceuticals

Fase 2/2

UB-612 (Multitope peptide based S1-RBD-protein based vaccine)

Subunidad Proteica

Vaxxinity

Fase 2/2

COVAX-19® Recombinant spike protein + adjuvant

Subunidad Proteica

Vaxine Pty Ltd./CinnaGen Co

Fase 2

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

Subunidad Proteica

Guangdong Provincial Center for Disease Control and Prevention/Gaozhou Center for Disease Control and Prevention

Fase 2

COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant

Subunidad Proteica

University of Saskatchewan

Fase 2

Razi Cov Pars, recombinant spike protein

Subunidad Proteica

Razi Vaccine and Serum Research Institute

Fase 2

Inactivada

Inactivada

Beijing Minhai Biotechnology Co. Ltd.

Fase 1/2

Vacuna basada en ADN (GX-19)

ADN

Genexine Consortium

Fase 1/2

Basada en RBD

Subunidad Proteica

Kentucky Bioprocessing

Fase 1/2

COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein

ADN

Takis + Rottapharm Biotech

Fase 1/2

Proteína S (producción de baculovirus)

Subunidad Proteica

Sanofi Pasteur/GSK

socio CAEME

Fase 1/2

Inactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 1018

Inactivada

The Government Pharmaceutical Organization (GPO) / PATH / Dynavax

Fase 1/2

GLS-5310

ADN

GeneOne Life Science

Fase 1/2

SC-Ad6-1, Adneviral vector vaccine

Vector viral no replicante

Tetherex Pharmaceuticals Corporation

Fase 1/2

AdCLD-CoV19 (adenovirus vector)

Vector viral no replicante

Cellid Co / Ltd

Fase 1/2

Subunidad de Proteína Potenciada (RBD)

Subunidad Proteica

Biological E Ltd

Fase 1/2

Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted (Nanocovax)

Subunidad Proteica

Nanogen Pharmaceutical Biotechnology

Fase 1/2

Recombinant SARS-CoV-2 Vaccine (CHO cell)

Subunidad Proteica

National Vaccine and Serum Institute China

Fase 1/2

SARS-CoV-2-RBD-Fc fusion protein

Subunidad Proteica

University Medical Center Groningen + Akston Biosciences Inc.

Fase 1/2

VSV-S

Vector viral replicante

Israel Institute for Biological Research/Weizmann Institute of Science

Fase 1/2

ARCT-021 

ARN

Arcturus/Duke-NUS

Fase 2

Recombinant protein vaccine S-268019 (using Baculovirus expression vector system)

Subunidad Proteica

Shionogi

Fase 1/2

COVIVAC. Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein +/- adjuvant CpG 1018

Vector viral no replicante

Institute of Vaccines and Medical Biologicals / Vietnam

Fase 1/2

Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF

Vector viral replicante

Aivita Biomedical Inc / National Institute of Health Research and Development / Ministry of Health Republic of Indonesia

Fase 1/2

CIGB-669 (RBD+AgnHB)

Subunidad Proteica

Center for Genetic Engineering and Biotechnology (CIGB)

Fase 1/2

LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens.

Vector viral no replicante

Shenzhen Geno-Immune Medical Institute

Fase 1/2

GBP510, a recombinant surface protein vaccine with adjuvant AS03 (aluminium hydroxide)

Subunidad Proteica

SK Bioscience Co Ltd and CEPI

Fase 1/2

EuCorVac-19; A spike protein using the recombinant protein technology and with an adjuvant.

Subunidad Proteica

POP Biotechnologies and EuBiologics Co Ltd

Fase 1/2

RBD-HBsAg VLPs

VLP

SpyBiotech/Serum Institute of India

Fase 1/2

CORVax – Spike (S) Protein Plasmid DNA Vaccine

ADN

Providence Health & Services

Fase 1

Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying mRNA (SAM) vectors expressing spike alone, or spike plus additional SARS-CoV-2 T cell epitopes.

Vector viral no replicante

Gritstone Oncology 

Fase 1

COH04S1 (MVA-SARS-2-S) – Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2

Vector viral no replicante

City of Hope Medical Center + National Cancer Institute

Fase 1

CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen

ARN

GlaxoSmithKline

Fase 1

COVIGEN 

ADN

University of Sydney / Bionet Co / Ltd Technovalia

Fase 1

CoV2-OGEN1, protein-based vaccine

Subunidad Proteica

VaxForm

Fase 1

Adjuvanted inactivated vaccine against SARS-CoV-2

Inactivada

The Scientific and Technological Research Council of Turkey (TÜBITAK)

Fase 1

MV-014-212, a live attenuated vaccine that expresses the spike (S) protein of SARS-CoV-2

Virus vivo atenuado

Meissa Vaccines / Inc.

Fase 1

AdimrSC-2f (recombinant RBD +/- Aluminium)

Subunidad Proteica

Adimmune Corporation

Fase 1

Live recombinant Newcastle Disease Virus (rNDV) vector vaccine

Inactivada

Laboratorio Avi-Mex

Fase 1

CoVepiT vaccine: SARS-CoV-2 multi-target peptide vaccine (targeting Spike, M, N, and several non-structural proteins)

Subunidad Proteica

OSE immunotherapeutics

Fase 1

ReCOV: Recombinant two-component spike and RBD protein COVID-19 vaccine (CHO cell).

Subunidad Proteica

Jiangsu Rec-Biotechnology

Fase 1

ChulaCov19 mRNA vaccine

ARN

Chulalongkorn University

Fase 1

Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs).

Vector viral replicante

Shenzhen Geno-Immune Medical Institute

Fase 1

SpFN (spike ferritin nanoparticle) uses spike proteins with a liposomal formulation QS21 (ALFQ) adjuvant.

Subunidad Proteica

Walter Reed Army Institute of Research (WRAIR)

Fase 1

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 

Subunidad Proteica

The University of Queensland

Fase 1

Tecnología de Virus quimérico VSV apto para replicación (VSVΔG) que administra la glucoproteína de la Espiga (S) del SARS-CoV-2.

Vector viral replicante

IAVI/Merck

socio CAEME

Fase 1

SK SARS-CoV-2 recombinant surface antigen protein subunit (NBP2001) + adjuvanted with alum.

Subunidad Proteica

SK Bioscience Co Ltd

Fase 1

Inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC)

Inactivada

Organization of Defensive Innovation and Research

Fase 1

Codificación de vector adenoviral simio de replicación defectuosa (GRAd) SARS-CoV-2 S

Vector viral no replicante

ReiThera/LEUKOCARE/Univercells

Fase 1

Ad5-nCoV

Vector viral no replicante

Institute of Biotechnology/ Academy of Military Medical Sciences/ PLA of China

Fase 1

Plataforma de vacuna oral

Vector viral no replicante

Vaxart

Fase 1

MVA-SARS-2-S

Vector viral no replicante

Ludwig-Maximilians/ University of Munich

Fase 1

Vacuna de subunidad de proteína S trimérica similar a la nativa

Subunidad Proteica

Clover Biopharmaceuticals Inc/GSK/Dynavax

socio CAEME

Fase 1

Proteína S recombinante con Advax ™ potenciador

Subunidad Proteica

Vaxine Pty Ltd/Medytox

Fase 1

Proteína S estabilizada por pinza molecular

Subunidad Proteica

University of Queensland/CSL/Seqirus

socio CAEME

Fase 1

Proteína S-2P + CpG 1018

Subunidad Proteica

Medigen Vaccine Biologics Corporation/NIAID/Dynavax

Fase 1

rRBD produced in CHO-cell chemically conjugate to tetanus toxoid

Subunidad Proteica

Instituto Finlay de Vacunas Cuba

Fase 1

RBD + Adjuvant

Subunidad Proteica

Instituto Finlay de Vacunas Cuba

Fase 1

ARNm

ARN

FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo

Fase 1

RBD (baculovirus production expressed in Sf9 cells)

Subunidad Proteica

West China Hospital/ Sichuan University

Fase 1

SARS-CoV-2 HLA-DR peptides

Subunidad Proteica

University Hospital Tuebingen

Fase 1

S1-RBD-protein

Subunidad Proteica

COVAXX

Fase 1

bacTRL-Spike

ADN

Symvivo

Fase 1

V591-001 – Measles-vector based (TMV-o38)

Vector viral replicante

Institute Pasteur/Themis/Univ of Pittsburg Center for Vaccine Research/Merck

socio CAEME

Fase 1

Intranasal flu-based-RBD

Vector viral no replicante

Beijing Wantai Biological Pharmacy/ Xiamen University

Fase 1

saRNA

ARN

Imperial College London

Fase 1

ARNm

ARN

People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.

Fase 1

[E1-, E2b-, E3-] hAd5- COVID19- Spike/nucleocápside

Vector viral no replicante

ImmunityBio Inc & NantKwest Inc

Fase 1

VLP vegetal

VLP

Medicago Inc.

Fase 1

DNA, engineered vaccine inserts compatible with multiple delivery systems

ADN

DIOSynVax Ltd / University of Cambridge

Pre-clínica

Live attenuated bacterial (Pertussis) Vector

LABV

Institut Pasteur Lille / Inserm

Pre-clínica

The 3 regions of SARS-Cov-2 Spike-protein: NTD, RBD and HR1-HR2 inserted into the plasmid of PcDNA3.1 (+).

ADN

Center of Genomics and Bioinformatics of Academy of Science of Republic of Uzbekistan

Pre-clínica

Live attenuated bacterial vector

LABV

ALtraBio / TheRex

Pre-clínica

msDNA vaccine

ADN

Mediphage Bioceuticals/University of Waterloo

Pre-clínica

DNA Immunostimulatory sequences

ADN

Inserm

Pre-clínica

DNA plasmid  vaccine encoding RBD

ADN

Vaccibody / Oslo Research Park / Norway

Pre-clínica

Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen

ARN

Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX)

Pre-clínica

Protein peptides with alum

Subunidad Proteica

Hacettepe University Turkey

Pre-clínica

Recombinant protein RBD fusion dimer adjuvanted vaccine (COVID-19 Vaccine Hipra)

Subunidad Proteica

HIPRA SCIENTIFIC SLU; LABORATORIOS HIPRA SA

Pre-clínica

S protein integrated in HIV VLPs

VLP

IrsiCaixa AIDS Research/IRTACReSA/Barcelona Supercomputing Centre/Grifols

Pre-clínica

Péptidos VLP / virus completo

VLP

Univ of Sao Paulo

Pre-clínica

Desconocida

Desconocida

Tulane University

Pre-clínica

ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes for multiple antigens, including the Spike (S) protein.

ARN

Ziphius Vaccines and Ghent University

Pre-clínica

eVLP – Partícula pseudovírica envolvente

VLP

ARTES Biotechnology

Pre-clínica

Encapsulated mRNA

ARN

CEA

Pre-clínica

Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid subunits vaccines using a plant expression vector.

Subunidad Proteica

Akdeniz University Department of Agricultural Biotechnology Antalya Turkey

Pre-clínica

Recombinant protein subunit vaccine

Subunidad Proteica

Pharmada Pharmaceuticals/TURKEY

Pre-clínica

Replicating VSV vector-based DC-targeting

Vector viral replicante

University of Manitoba

Pre-clínica

Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 protein: rNDV-LS1-S1-F/SARS-CoV-2

Vector viral replicante

Farmacológicos Veterinarios SAC (FARVET SAC)

Pre-clínica

VLP

VLP

OSIVAX

Pre-clínica

Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD protein: rNDV-LS1-HN-RBD/SARS-CoV-2

Vector viral replicante

Farmacológicos Veterinarios SAC (FARVET SAC)

Pre-clínica

Recombinant SARS CoV-2 RBD Protein, Alum adjuvanted

Subunidad Proteica

Bio Farma + Baylor College Medicine

Pre-clínica

Lentiviral Vector

Vector viral no replicante

Theravectys – Institut Pasteur

Pre-clínica

Recombinant Protein Vaccine

Subunidad Proteica

Ataturk University Vaccine Research Center (Erzurum) and Health Institutes of Turkey (TUSEB)

Pre-clínica

Recombinant Spike Protein

Subunidad Proteica

CinnaGen Co

Pre-clínica

Protein Subunit Adenoviral Carrier

Subunidad Proteica

CEA CNRS

Pre-clínica

Protein Subunit Nanoformulated

Subunidad Proteica

Vaxinano CEA INRAE

Pre-clínica

Soluble recombinant S protein produced in CHO cells

Subunidad Proteica

Center for Advanced Technologies Uzbekistan

Pre-clínica

Adjuvanted Peptides + Recombinant Spike Protein

Subunidad Proteica

Yıldız Technical University Turkey

Pre-clínica

NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and other viral proteins

Subunidad Proteica

Arizona State University

Pre-clínica

Desconocida

VLP

Doherty Institute

Pre-clínica

ADDomerTM con display de multiepítopo

VLP

Imophoron Ltd and Bristol University’s Max Planck Centre

Pre-clínica

Protein DC-targeted epitopes

Subunidad Proteica

LinkinVax VRI Inserm

Pre-clínica

Lentiviral Vector Retro-VLP Particles

Vector viral no replicante

Sorbonne University

Pre-clínica

Partículas pseudovíricas, basada en RBD de VLP

VLP

Saiba GmbH

Pre-clínica

Sendai virus vector

Vector viral no replicante

Max Planck Institute for Biochemstry / vir4vac Germany

Pre-clínica

Spiked-based

Subunidad Proteica

Nanografi Nano Technology Middle East Technical University Ankara University

Pre-clínica

Lentiviral Vector

Vector viral no replicante

AIOVA

Pre-clínica

Adenovirus Type 5 Vector

Vector viral no replicante

Globe Biotech Limited / Bangladesh

Pre-clínica

Sendai virus vector

Vector viral no replicante

ID Pharma

Pre-clínica

Codon deoptimized live attenuated vaccines

Virus vivo atenuado

Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S

Pre-clínica

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018

Inactivada

Institute Butantan (Brazil) / Dynavax / PATH

Pre-clínica

Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein (N) expressed in E.coli

Subunidad Proteica

FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines)

Pre-clínica

Partículas pseudovíricas, vehículos lentivirus y baculovirus

VLP

Oncoimmunology group

Pre-clínica

VLP + adyuvante

VLP

Mahidol University/ The Government Pharmaceutical Organization (GPO)

Pre-clínica

DNA plasmids containing S-gene

ADN

Biosun Pharmed

Pre-clínica

Adeno5-based

Vector viral no replicante

Erciyes University

Pre-clínica

mRNA

ARN

Selcuk University

Pre-clínica

ARNm

ARN

IDIBAPS-Hospital Clinic Spain

Pre-clínica

RBD-protein

Subunidad Proteica

Mynvax

Pre-clínica

Peptide + novel adjuvant

Subunidad Proteica

Bogazici University

Pre-clínica

Inactivada

Inactivada

Erciyes University

Pre-clínica

Newcastle disease virus expressing membrane-anchored spike

Vector viral no replicante

Icahn School of Medicine at Mount Sinai

Pre-clínica

Inactivated whole virus

Inactivada

National Research Centre/Egypt

Pre-clínica

ARNm

ARN

Greenlight Biosciences

Pre-clínica

ARNm en sistema de administración intranasal

ARN

eTheRNA

Pre-clínica

Recombinant S protein

Subunidad Proteica

Max-Planck-Institute of Colloids and Interfaces

Pre-clínica

Self-amplifying RNA

ARN

Gennova

Pre-clínica

RBD protein delivered in mannoseconjugated chitosan nanoparticle

Subunidad Proteica

Ohio State University / Kazakh National Agrarian University

Pre-clínica

DNA plasmid vaccine S,S1,S2,RBD &N

ADN

National Research Centre/Egypt

Pre-clínica

ARNm de LNP

ARN

Chula Vaccine Research Center/University of Pennsylvania

Pre-clínica

VSV-S

Vector viral replicante

Aurobindo

Pre-clínica

Peptides

Subunidad Proteica

Neo7Logic

Pre-clínica

Enveloped Virus-Like Particle (eVLP)

VLP

VBI Vaccines Inc.

Pre-clínica

Recombinant spike protein with Essai O/W 1849101 adjuvant

Subunidad Proteica

Kazakh National Agrarian University Kazakhstan / National Scientific Center for Especially Dangerous Infections

Pre-clínica

ARNm

ARN

China CDC/Tongji University/Stermina

Pre-clínica

VLP

VLP

Middle East Technical University

Pre-clínica

Recombinant S protein

Subunidad Proteica

Izmir Biomedicine and Genome Center

Pre-clínica

Inactivated + Alum

Inactivada

Shifa Pharmed

Pre-clínica

Protein Subunit S,N,M&S1 protein

Subunidad Proteica

National Research Centre/Egypt

Pre-clínica

Inactivada

Inactivada

Selcuk University

Pre-clínica

Virus-like particle-based Dendritic Cell(DC)- targeting vaccine

VLP

University of Manitoba

Pre-clínica

Inactivated

Inactivada

Zista Kian Azma Co

Pre-clínica

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018

Inactivada

Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH

Pre-clínica

Plant derived VLP

VLP

Shiraz University

Pre-clínica

Recombinant S protein produced in BEVS

Subunidad Proteica

Tampere University

Pre-clínica

Varios candidatos de ARNm

ARN

RNAimmune Inc

Pre-clínica

VLP

VLP

Bezmialem Vakif University

Pre-clínica

MVA expressing structural proteins

Vector viral no replicante

Centro Nacional Biotecnología (CNB-CSIC) Spain

Pre-clínica

RBD protein (baculovirus production) + FARSqualene adjuvant

Subunidad Proteica

Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)

Pre-clínica

D614G variant LNP-encapsulated mRNA

ARN

Globe Biotech Ltd

Pre-clínica

ARNm encapsulado en liposomas

ARN

BIOCAD

Pre-clínica

ARNm encapsulado en LNP

ARN

University of Tokyo/ Daiichi- Sankyo

Pre-clínica

Adenovirus-based

Vector viral no replicante

Ankara University

Pre-clínica

Influenza A H1N1 vector

Vector viral no replicante

National Research Centre/Egypt

Pre-clínica

S-Protein (Subunit) + Adjuvant, E coli based Expression

Subunidad Proteica

Helix Biogen Consult. Ogbomoso & Trinity Immonoefficient Laboratory/Ogbomoso. Oyo State/Nigeria.

Pre-clínica

Replicación de ARN derivados de SARS-CoV-2 defectuoso

ARN

Centro Nacional Biotecnología (CNB-CSIC) Spain

Pre-clínica

DNA vaccine

ADN

Ege University

Pre-clínica

ARNm encapsulado en LNP que codifica RBD

ARN

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

Pre-clínica

Cóctel de ARNm encapsulado en LNP que codifica VLP

ARN

Fudan University/ Shanghai JiaoTong University/RNACure Biopharma

Pre-clínica

LNP-mRNA

ARN

CanSino Biologics/Precision NanoSystems

Pre-clínica

ARNm de LNP

ARN

Translate Bio/Sanofi Pasteur

socio CAEME

Pre-clínica

DNA plasmid vaccine RBD&N

ADN

Scancell/University of Nottingham/ Nottingham Trent University

Pre-clínica

Subunidad proteica

Subunidad Proteica

Research Institute for Biological Safety Problems/Rep of Kazakhstan

Pre-clínica

Vector de paramixovirus aviar (APMV)

Vector viral replicante

The Lancaster University UK

Pre-clínica

S subunit intranasal liposomal formulation with GLA/3M052 adjs.

Subunidad Proteica

University of Virginia

Pre-clínica

Recombinant protein

Subunidad Proteica

Yisheng Biopharma

Pre-clínica

Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD

Vector de bacteria replicante

Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH)

Pre-clínica

Vector del virus de la enfermedad de Newcastle (NDV- SARS-CoV-2/Espiga)

Vector viral replicante

Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ

Pre-clínica

Inactivated

Inactivada

Milad Pharmaceutics Co

Pre-clínica

Vector de influenza de replicación única sin M2

Vector viral replicante

UW–Madison/FluGen/Bharat Biotech

Pre-clínica

Inactivated + alum

Inactivada

KM Biologics

Pre-clínica

Vector VSV

Vector viral replicante

FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo

Pre-clínica

VSV-S

Vector viral replicante

University of Western Ontario

Pre-clínica

Vector de influenza expresando RBD

Vector viral replicante

University of Hong Kong

Pre-clínica

Influenza atenuada que expresa una porción antigénica de la proteína S

Vector viral replicante

Fundação Oswaldo Cruz and Instituto Buntantan

Pre-clínica

Inactivada

Inactivada

Kocak Farma Ilac ve Kimya San. A.S.

Pre-clínica

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018

Inactivada

Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH

Pre-clínica

Ad 5 vector for intranasal administration

Vector viral no replicante

University of Helsinki & University of Eastern Finland

Pre-clínica

Vacuna recombinante basada en el virus de la influenza A, para la prevención de COVID- 19 (intranasal)

Vector viral replicante

FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo

Pre-clínica

Vacuna viva viral vectorizada basada en la cadena atenuada del virus de la influenza (intranasal)

Vector viral replicante

BiOCAD and IEM

Pre-clínica

Vector de HSPV expresando proteína S

Vector viral replicante

Tonix Pharma/Southern Research

Pre-clínica

Virus del sarampión (objetivos S, N)

Vector viral replicante

DZIF – German Center for Infection Research

Pre-clínica

mRNA

ARN

Providence Therapeutics

Pre-clínica

Vector de sarampión

Vector viral replicante

FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo

Pre-clínica

DNA plasmid vaccine

ADN

Globe Biotech Limited / Bangladesh

Pre-clínica

Vector de sarampión

Vector viral replicante

Zydus Cadila

Pre-clínica

Vector YF17D

Vector viral replicante

KU Leuven

Pre-clínica

Basada en espiga (barrido de epítopo)

Subunidad Proteica

ImmunoPrecise

Pre-clínica

Péptido de vesícula de membrana externa (OMV)

Subunidad Proteica

Intravacc/Epivax

Pre-clínica

Subunidad de vesícula de membrana externa (OMV)

Subunidad Proteica

Intravacc/Epivax

Pre-clínica

Basada en RBD

Subunidad Proteica

Neovii/Tel Aviv University

Pre-clínica

Subunidad proteica

Subunidad Proteica

MOGAM Institute for Biomedical Research GC Pharma

Pre-clínica

Péptidos derivados de Proteína de espiga

Subunidad Proteica

Axon Neuroscience SE

Pre-clínica

Administración oral, subunidad estable al calor

Subunidad Proteica

Applied Biotechnology Institute Inc

Pre-clínica

Proteína S recombinante en sistema de vector de expresión de baculovirus de células de insecto (IC-BEVS)

Subunidad Proteica

Vabiotech

Pre-clínica

Proteína de fusión recombinante S1-Fc

Subunidad Proteica

AnyGo Technology

Pre-clínica

Basado en espiga

Subunidad Proteica

University of Alberta

Pre-clínica

Partículas esféricas estructuralmente modificadas del virus del mosaico del tabaco (TMV)

Subunidad Proteica

Lomonosov Moscow State University

Pre-clínica

Vacuna basada en OMV

Subunidad Proteica

BiOMViS Srl/Univ of Trento

Pre-clínica

Plasmid DNA, Needle-Free Delivery

ADN

Immunomic Therapeutics Inc./EpiVax Inc.

Pre-clínica

LNP-encapsulated mRNA encoding S

ARN

Max-Planck-Institute of Colloids and Interfaces

Pre-clínica

Plasmid DNA, nanostructured RBD

ADN

National institute of Chemistry Slovenia

Pre-clínica

Vacuna basada en OMV

Subunidad Proteica

Quadram Institute Biosciences

Pre-clínica

Subunidad basada en vegetales (RBD-Fc + Adyuvante)

Subunidad Proteica

Baiya Phytopharm/ Chula Vaccine Research Center

Pre-clínica

Vacuna de nanopartículas

Subunidad Proteica

LakePharma Inc.

Pre-clínica

Sistema de expresión de proteínas S y N basado en vacunal oral E. coli

Subunidad Proteica

MIGAL Galilee Research Institute

Pre-clínica

mRNA

ARN

Cell Tech Pharmed

Pre-clínica

Vacuna candidata de péptido largo sintético para proteínas S y M

Subunidad Proteica

OncoGen

Pre-clínica

Potenciada – péptido de microesferas

Subunidad Proteica

VIDO-InterVac University of Saskatchewan

Pre-clínica

COVID-19 XWG-03 – proteínas truncadas S (espiga)

Subunidad Proteica

Innovax/Xiamen Univ/GSK

socio CAEME

Pre-clínica

Proteína recombinante, nanopartículas (a base de proteína S y otros epítopos)

Subunidad Proteica

Saint-Petersburg scientific research institute of vaccines and serums

Pre-clínica

Subunidad proteica, Fuente vegetal

Subunidad Proteica

iBio/CC-Pharming

Pre-clínica

Proteína S1 o RBD

Subunidad Proteica

Baylor College of Medicine

Pre-clínica

Vacuna de subunidades

Subunidad Proteica

FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo

Pre-clínica

Cadena principal gp-96

Subunidad Proteica

Heat Biologics/Univ. Of Miami

Pre-clínica

Vacuna peptídica

Subunidad Proteica

FBRI SRC VB VECTOR Rospotrebnadzor Koltsovo

Pre-clínica

Subunidad de Proteína EPV- CoV-19

Subunidad Proteica

EpiVax

Pre-clínica

saRNA formulated in a NLC

ARN

Infectious Disease Research Institute/ Amyris Inc

Pre-clínica

Proteína S

Subunidad Proteica

EpiVax/Univ of Georgia

Pre-clínica

Péptido Ii-Key

Subunidad Proteica

Generex/EpiVax

Pre-clínica

Proteína S

Subunidad Proteica

AJ Vaccines

Pre-clínica

Péptido

Subunidad Proteica

Flow Pharma Inc

Pre-clínica

Péptido

Subunidad Proteica

Vaxil Bio

Pre-clínica

Subunidad S1 con Matriz de microagujas

Subunidad Proteica

University of Pittsburgh

Pre-clínica

Proteína recombinante de VLP + adyuvante

Subunidad Proteica

Japan

Pre-clínica

Proteína S + adyuvante

Subunidad Proteica

National Institute of Infectious Disease Japan

Pre-clínica

Proteína S

Subunidad Proteica

WRAIR/USAMRIID

Pre-clínica

Antígenos peptídicos formulados en LNP

Subunidad Proteica

IMV Inc

Pre-clínica

VLP del sistema de expresión de células S2 de insecto Drosophila

Subunidad Proteica

ExpreS2ion

Pre-clínica

Partícula tipo cápside

Subunidad Proteica

AdaptVac (PREVENT-nCoV consortium)

Pre-clínica

Dominio de unión al receptor (RBD) en la proteína de fusión con región constante (Fc) de la inmunoglobulina G (IgG) + Adyuvante.

Subunidad Proteica

Chulalongkorn University/GPO Thailand

Pre-clínica

Subunidad proteica

Subunidad Proteica

University of San Martin and CONICET Argentina

Pre-clínica

Vacuna inactivada contra el SARS-CoV2 basada en influenza + Potenciador

Vector viral no replicante

National Center for Genetic Engineering and Biotechnology (BIOTEC) /GPO Thailand

Pre-clínica

viral de la rabia recombinante desactivada que contiene S1

Vector viral no replicante

Bharat Biotech/Thomas Jefferson University

Fase 1

Vacuna basada en el virus de la parainfluenza 5 (PIV5) que expresa la proteína S

Vector viral no replicante

University of Georgia/University of Iowa

Pre-clínica

Measles Vector

Vector viral no replicante

Cadila Healthcare Limited

Pre-clínica

Vacuna basada en células dendríticas

Vector viral no replicante

University of Manitoba

Pre-clínica

Proteínas estructurales que expresan MVA

Vector viral no replicante

Centro Nacional Biotecnología (CNB-CSIC)

Pre-clínica

basada en adenovirus + péptidos unidos al antígeno leucocitario humano (HLA)

Vector viral no replicante

Valo Therapeutics Ltd

Pre-clínica

Ad5 S oral

Vector viral no replicante

Stabilitech Biopharma Ltd

Pre-clínica

Ad5 S (plataforma GREVAX™)

Vector viral no replicante

Greffex

Pre-clínica

Recombinant spike with adjuvant

Subunidad Proteica

Iran

Pre-clínica

NasoVAX basada en adenovirus que expresa la proteína S de SARS2-CoV

Vector viral no replicante

Altimmune

Pre-clínica

MVA-S

Vector viral no replicante

IDIBAPS-Hospital Clinic Spain

Pre-clínica

Codificada con MVA-S

Vector viral no replicante

DZIF – German Center for Infection Research

Pre-clínica

Partículas pseudovíricas (VLP) codificadas con MVA

Vector viral no replicante

GeoVax/BravoVax

Pre-clínica

Vector de virus adeno-asociado (AAVCOVID)

Vector viral no replicante

Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis

Pre-clínica

Newcastle disease virus expressing S

Vector viral no replicante

Icahn School of Medicine at Mount Sinai

Pre-clínica

Vacuna viva atenuada desoptimizada por codones

Virus vivo atenuado

Indian Immunologicals Ltd/Griffith University

Pre-clínica

Vacuna viva atenuada desoptimizada por codones

Virus vivo atenuado

Codagenix/Serum Institute of India

Pre-clínica

mRNA

ARN

ReNAP Co

Pre-clínica

Inactivada + CpG 1018

Inactivada

Valneva/Dynavax

Pre-clínica

Inactivada + CpG 1018

Inactivada

Sinovac/Dynavax

Pre-clínica

TBD

Inactivada

Osaka University/ BIKEN/ NIBIOHN

Pre-clínica

Vacuna de ADN

ADN

Entos Pharmaceuticals

Pre-clínica

Vacuna de ADN

ADN

University of Waterloo

Pre-clínica

ADN plasmídico, de inyección sin aguja

ADN

Inc./PharmaJet

Pre-clínica

Vacuna de ADN

ADN

BioNet Asia

Pre-clínica

VLP

VLP

Max Planck Institute for Dynamics of Complex Technical Systems

Pre-clínica

AND

ADN

Takis/Applied DNA Sciences/Evvivax

Pre-clínica

CD8 T cell peptide targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins

T-cell based

OSE immunotherapeutics

Pre-clínica

ADN con electroporación

ADN

Chula Vaccine Research Center

Pre-clínica

VLPs produced in BEVS

VLP

Tampere University

Pre-clínica

ADN con electroporación

ADN

Karolinska Institute / Cobra Biologics (OPENCORONA Project)

Pre-clínica

i

Fuentes:

Organización Mundial de la Salud

Cada vacuna tiene un largo proceso de desarrollo e implica un gran hallazgo para la salud. Te compartimos este video para que conozcas más: